



**Universiteit
Leiden**
The Netherlands

Targeting tumors using T-cell receptor gene transfer: a balance between efficacy and safety

Amerongen, R.A. van

Citation

Amerongen, R. A. van. (2023, November 30). *Targeting tumors using T-cell receptor gene transfer: a balance between efficacy and safety*. Retrieved from <https://hdl.handle.net/1887/3665306>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3665306>

Note: To cite this publication please use the final published version (if applicable).

TARGETING TUMORS USING T-CELL RECEPTOR GENE TRANSFER

A BALANCE BETWEEN EFFICACY AND SAFETY

Rosa van Amerongen

Targeting tumors using T-cell receptor gene transfer
A balance between efficacy and safety

ISBN: 978-94-6419-954-3
Cover: BioRender.com, Rosa van Amerongen & Ilse Modder
Lay-out: Ilse Modder | www.ilsemodder.nl
Printed by: Gildeprint Enschede | www.gildeprint.nl

The research presented in this thesis was performed at the Department of Hematology of the Leiden University Medical Center and was financially supported by Health Holland (grant number LSHM15011) and Bellicum Pharmaceuticals (unrestricted grant).

© 2023 R.A. van Amerongen
All rights reserved. No part of this thesis may be reproduced or transmitted in any form or by any means without prior written permission of the author.

TARGETING TUMORS USING T-CELL RECEPTOR GENE TRANSFER

A BALANCE BETWEEN EFFICACY AND SAFETY

Proefschrift

ter verkrijging van
de graad van doctor aan de Universiteit Leiden,
op gezag van rector magnificus prof.dr.ir. H. Bijl,
volgens besluit van het college voor promoties
te verdedigen op donderdag 30 november 2023
klokke 13.45 uur

door

Rosa Annabel van Amerongen

geboren te Velsen

in 1991

Promotores

Prof. dr. J.H.F. Falkenburg
Prof. dr. M.H.M. Heemskerk

Leden promotiecommissie

Prof. dr. J.J. Zwaginga
Prof. dr. S.H. van der Burg
Dr. I. Jedema (Nederlands Kanker Instituut)
Prof. dr. T.D. de Gruijl (Amsterdam Universitair Medische Centra)

TABLE OF CONTENTS

| | | |
|------------|--|-----|
| Chapter 1 | General introduction and aim of the thesis | 9 |
| Chapter 2 | WT1-specific TCRs directed against newly identified peptides install antitumor reactivity against acute myeloid leukemia and ovarian carcinoma | 31 |
| Chapter 3 | Human iPSC-derived preclinical models to identify toxicity of tumor-specific T cells with clinical potential | 69 |
| Chapter 4 | PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer | 97 |
| Chapter 5 | TCR-based therapy for prostate cancer targeting KLK3 (PSA) and KLK4 | 141 |
| Chapter 6 | Summary and general discussion | 177 |
| Appendices | Nederlandse samenvatting | 194 |
| | List of publications | 201 |
| | Curriculum vitae | 203 |
| | Dankwoord | 205 |